Comments Regarding New Dietary Ingredients and Dietary Supplements Subject to Requirement for Pre-Market Notification

Share page:
Docket Number:

CHPA believes that FDA’s issuance of the 2022 Draft Guidance is premature. Instead, FDA’s priority should be on finalizing the 2016 Draft NDI Guidance and clarifying unanswered questions about the scope and applicability of the NDI notification requirement.